BioSpace News Archive

Today, Movano Inc. (NASDAQ:MOVE), a health technology company designing devices that empower individuals to optimize their health in order to help prevent and better manage chronic diseases, reported financial results for the three months ending September 30, 2021 and provided a business update.

Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis to advance the science of precision health, today announced that members of its executive leadership team will participate in a virtual fireside chat discussion at the Canaccord Genuity Virtual MedTech, Diagnostics and Digital Health & Services Forum on Nov. 18 at 8:30 a.m., EST.

Celltrion Group announced today that the European Medicine’s Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) issued a positive scientific opinion recommending marketing authorisation for regdanvimab (CT-P59), a monoclonal antibody treatment for adults with COVID-19 that do not require supplemental oxygen and who are at increased risk of progressing to severe COVID-19.

Alligator Bioscience AB and Aptevo Therapeutics announce preclinical data on ALG.APV-527, a potentially first-in-class bispecific targeting both 4-1BB and tumor antigen 5T4 will be presented in a poster at the Society of Immunotherapy Cancer’s 36th Annual Meeting, taking place virtually and in-person November 12- 14, 2021 in Washington D.C.

Collegium Pharmaceutical, Inc., a specialty pharmaceutical company committed to being the leader in responsible pain management, announced that management will participate in the following investor conferences.

Cipher Pharmaceuticals Inc. (TSX: CPH) (“Cipher” or “the Company”) today announced its financial and operating results for the three and nine months ended September 30, 2021.

Biogen Inc. (Nasdaq: BIIB) and Eisai Co., Ltd. (Tokyo, Japan) announced that data from approximately 7,000 plasma samples from more than 1,800 patients in the ADUHELM™ (aducanumab-avwa) Phase 3 clinical trials showed a statistically significant correlation between plasma p-tau reduction and less cognitive and functional decline in Alzheimer’s disease.

Cyclerion Therapeutics, Inc., a clinical-stage biopharmaceutical company on a mission to develop treatments that restore cognitive function, announced that management will attend the Jefferies London Healthcare Conference on Nov. 16th to 18th, 2021.

Adaptive Biotechnologies Corporation announced that Palmetto GBA’s Molecular Diagnostics Program has finalized a local coverage determination which supports the Medicare coverage for clonoSEQ® to detect and monitor minimal residual disease in patients with B-cell acute lymphoblastic leukemia, multiple myeloma and chronic lymphocytic leukemia.

MediciNova, Inc.,today announced that MediciNova’s research collaborator Masatsune Ogura, M.D., Ph.D., Associate Professor at the Department of General Medical Science, Chiba University Graduate School of Medicine, is presenting results and findings of a study that investigated the mechanism by which MN-001 (tipelukast) alters triglyceride (TG) metabolism in hepatocytes at The Liver Meeting® 2021.